Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) – Pipeline Review, H2 2016’, provides in depth analysis on Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)

The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

4SC AG

Acetylon Pharmaceuticals, Inc.

Chipscreen Biosciences Ltd

Curis, Inc.

GlaxoSmithKline Plc

HitGen LTD

Italfarmaco S.p.A.

MEI Pharma, Inc.

Merck & Co., Inc.

Rodin Therapeutics

Sigma-Tau S.p.A.

TetraLogic Pharmaceuticals

Yungjin Pharm. Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) Overview 8

Therapeutics Development 9

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) - Products under Development by Stage of Development 9

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) - Products under Development by Therapy Area 10

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) - Products under Development by Indication 11

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) - Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) - Products under Development by Companies 15

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) - Products under Development by Universities/Institutes 20

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) - Therapeutics Assessment 22

Assessment by Monotherapy/Combination Products 22

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) - Companies Involved in Therapeutics Development 28

4SC AG 28

Acetylon Pharmaceuticals, Inc. 29

Chipscreen Biosciences Ltd 30

Curis, Inc. 31

GlaxoSmithKline Plc 32

HitGen LTD 33

Italfarmaco S.p.A. 34

MEI Pharma, Inc. 35

Merck & Co., Inc. 36

Rodin Therapeutics 37

Sigma-Tau S.p.A. 38

TetraLogic Pharmaceuticals 39

Yungjin Pharm. Co., Ltd. 40

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) - Drug Profiles 41

4SC-202 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ACY-738 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ACY-957 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

CS-3158 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

CUDC-907 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

givinostat - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

HG-3001 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Largazole - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

N-140 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

pracinostat - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

remetinostat - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Small Molecule to Inhibit HDAC2 for Oncology - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Small Molecules to Inhibit HDAC2 for Neurological Disorders - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

ST-3595 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

tucidinostat - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

vorinostat - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

YPL-001 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) - Dormant Projects 78

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC

3.5.1.98) - Featured News & Press Releases 81

Aug 01, 2016: MEI Pharmas Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy 81

Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 81

Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 82

May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One 82

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 83

Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 83

Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 84

Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 84

Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 85

Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study 85

Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models 86

Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 87

Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting 89

Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 89

Oct 06, 2015: MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting 90

Appendix 91

Methodology 91

Coverage 91

Secondary Research 91

Primary Research 91

Expert Panel Validation 91

Contact Us 91

Disclaimer 92

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Products under Development by Companies, H2 2016 (Contd..2) 18

Products under Development by Companies, H2 2016 (Contd..3) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Products under Investigation by Universities/Institutes, H2 2016 21

Assessment by Monotherapy/Combination Products, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 27

Pipeline by 4SC AG, H2 2016 28

Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 29

Pipeline by Chipscreen Biosciences Ltd, H2 2016 30

Pipeline by Curis, Inc., H2 2016 31

Pipeline by GlaxoSmithKline Plc, H2 2016 32

Pipeline by HitGen LTD, H2 2016 33

Pipeline by Italfarmaco S.p.A., H2 2016 34

Pipeline by MEI Pharma, Inc., H2 2016 35

Pipeline by Merck & Co., Inc., H2 2016 36

Pipeline by Rodin Therapeutics, H2 2016 37

Pipeline by Sigma-Tau S.p.A., H2 2016 38

Pipeline by TetraLogic Pharmaceuticals, H2 2016 39

Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 40

Dormant Projects, H2 2016 78

Dormant Projects (Contd..1), H2 2016 79

Dormant Projects (Contd..2), H2 2016 80

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 22

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports